Clinical Trial Update: Study of Dexycu in Treating Intraocular Inflammation [Phase 3]

View source ↗

Summary

A Phase 3 trial of Dexycu for intraocular inflammation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataract
• Intraocular Inflammation

Drugs mentioned

• Dexycu (dexamethasone intraocular suspension)

Snippet

Sponsor: Ocumension Therapeutics (Shanghai) Co., Ltd | Conditions: Inflammation, Cataract | Phase 3 | Status: COMPLETED